NEW YORK – Singular Genomics Systems said this week that its acquisition by Deerfield Management Company has closed following a vote by its stockholders on Feb. 19. Singular now operates as a private company, and trading of its common stock on the Nasdaq has been suspended. The deal, under which Deerfield acquired all of Singular's outstanding shares of common stock for $20 per share in cash, was originally announced in late December.
T2 Biosystems this week said in documents filed with the US Securities and Exchange Commission that it has engaged an advisory firm to sell the company and its assets, including its patents and other intellectual property. Earlier this week, T2 announced it had laid off substantially all of its employees, fired its top executives, and reappointed those executives to part-time consulting roles.
Revvity said this week that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group related to the Spotfire software. The ruling follows a preliminary injunction issued in April 2024. Spotfire is a data analytics and visualization platform that is used in life sciences research and clinical trials, among other industries.
Agilent Technologies said this week that its board of directors has approved a quarterly dividend of $.25 per share of its common stock, payable on April 23 to shareholders of record on April 1.
Danaher this week announced that its board of directors has approved a regular quarterly cash dividend of $.32 per share of its common stock, payable on April 25 to holders of record on March 28.
Bruker said this week that its board of directors has approved a quarterly cash dividend of $.05 per share of the company's common stock. The dividend will be paid on March 28 to stockholders of record as of March 17.
Abbott said this week that its board of directors has declared a quarterly dividend of $.59 per share. The cash dividend will be paid on May 15 to shareholders of record as of April 15.
AccessDx Laboratory, a CLIA-certified, CAP-accredited, and New York State Department of Health-approved diagnostic laboratory, this week announced an expanded integration with the PointClickCare healthcare technology platform. The integration allows for the delivery of pharmacogenomic (PGx) risk assessments, advanced diagnostic test results, and ongoing PGx monitoring to healthcare providers in the PointClickCare network, which provides long-term care to seniors.
PAVmed subsidiary Lucid Diagnostics said this week that it has entered into its first concierge medicine contract with LEAA Health. The contract provides LEAA Health's members with access to Lucid's EsoGuard Esophageal DNA test as part of their personalized care service on a cash-pay basis. Lucid said it aims to drive "contractually guaranteed revenue by capitalizing on the growing demand for prevention-focused healthcare services in the expanding concierge medicine market."
New York-based bioinformatics firm Basepair and TrendBio, a supplier of medical research equipment, said last week that TrendBio will distribute Basepair's analysis and visualization platform for sequencing data to researchers in Australia and New Zealand.
Shift Bioscience of Cambridge, UK, said this week that it has established a North American facility in Toronto, Canada, to advance development of its AI-powered virtual cell technology.
German test components supplier Applyo Jena said this week that it has completed a Series A funding round that was led by Bosch Ventures with participation from LBBW Venture Capital. The firms did not disclose the amount that was raised. Applyo Jena uses freeze-drying technology to offer lyophilized reagents and enzymes with extended shelf lives, stability at ambient temperatures, and improved ease of use compared to liquid components. It plans to use the Series A funding to accelerate its international expansion and offer its components for use in the diagnostic, pharmaceutical, and life sciences markets.
In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.